【摘要】 目的探讨联合检测乙型肝炎(下称乙肝)病毒血清标志物两对半定量、乙肝病毒(HBV)DNA定量与前S2抗原对乙肝患者诊断和预后的意义。方法分别使用酶联免疫吸附试验(ELISA)法、荧光定量PCR(FQ-PCR)和化学发光微粒子免疫分析技术(CMIA)对141例乙肝患者的乙肝病毒前S2抗原(Pre-S2)、乙肝病毒DNA(HBV-DNA)、乙肝两对半进行定性和(或)定量检测。结果137例HBsAg阳性患者中Pre-S2阳性119例,HBeAg阳性69例,HBV-DNA阳性84例,阳性率Pre-S2>HBV-DNA>HBeAg。结论联合检测乙肝病毒血清标志物两对半、HBV-DNA定量及Pre-S2,可以更全面地反映临床HBV感染、复制、传染性及抗病毒治疗效果的状况。更多还原

【Abstract】 Objective To explore the clinical significance of detecting serological markers,HBV and Pre-S2 together.Methods 141 samples from the patients with HBV were tested for the serological markers,HBV-DNA and Pre-S2 by CMIA,FQ-PCR and ELISA individually.Results The HBsAg in 137 cases and the Pre-S2 in 119 cases were positive, the HBeAg in 69 cases and HBV-DNA in 84 cases were positive.The positive rate of the Pre-S2 was highest in three, and the positive rate of the HBeAg was lowest.Conclusion The united detection of serological markers, HBV-DNA and Pre-S2 can be used to reflect HBV infection,duplication,contagiousness and the curative effect of anti-virus therapy.更多还原